NewAmsterdam Pharma to Conduct Interim Analysis in Q4 2026
"Our clinical execution remains strong. We have completed enrollment in REMBRANDT and continue to advance PREVAIL and RUBENS - three Phase 3 trials that underscore the breadth and maturity of our development program," said Michael Davidson, Chief Executive Officer of NewAmsterdam Pharma. "We are excited following an initial blinded review of PREVAIL data after the two-year anniversary of enrollment completion - which showed a Year 1 overall MACE event rate consistent with BROADWAY and a Year 1-to-Year 2 overall MACE event rate lower than expected - and we have decided to conduct an interim analysis in the fourth quarter of 2026. This timing coincides with the minimum 2.5-year follow-up for the trial. We are optimistic about the interim analysis and expect to report the result of the analysis in the first quarter of 2027. Should the trial not stop for efficacy at that time, we anticipate completion by the end of 2027. We will provide further details at our annual Investor Day on August 5, 2026."
